DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)

Press/Media: Press / Media

PeriodJun 9 2021

Media coverage

6

Media coverage

  • TitleDURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)
    Media name/outletYahoo! Finance
    CountryUnited States
    Date6/9/21
    PersonsEric J Lawitz
  • TitleDURECT CORPORATION : to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)
    Media name/outletMarketScreener.com
    CountryUnited States
    Date6/9/21
    PersonsEric J Lawitz
  • TitleDURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)
    Media name/outletProfitQuotes.com
    CountryUnited States
    Date6/9/21
    PersonsEric J Lawitz
  • TitleDURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)
    Media name/outletFinanzen.ch
    CountrySwitzerland
    Date6/9/21
    PersonsEric J Lawitz
  • TitleDURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)
    Media name/outletBioSpace
    CountryUnited States
    Date6/9/21
    PersonsEric J Lawitz
  • TitleDURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)
    Media name/outletWFMZ-TV Online
    CountryUnited States
    Date6/9/21
    PersonsEric J Lawitz